{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:20:31Z","timestamp":1779312031506,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ajem.2024.08.033","type":"journal-article","created":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T01:01:48Z","timestamp":1725152508000},"page":"59-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Gabapentinoid prescribing patterns and predictors utilizing neural networks: An analysis across emergency departments Nationwide between 2012 and 2021"],"prefix":"10.1016","volume":"85","author":[{"given":"Christine","family":"Ramdin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryann","family":"Mazer-Amirshahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2024.08.033_bb0005","article-title":"Call for increased pharmacovigilance of gabapentin","volume":"359","author":"Peckham","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.ajem.2024.08.033_bb0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-0404.1999.tb07389.x","article-title":"Gabapentin: a new tool in the treatment of neuropathic pain","volume":"173","author":"Harden","year":"1999","journal-title":"Acta Neurol Scand Suppl"},{"issue":"3","key":"10.1016\/j.ajem.2024.08.033_bb0015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/dmcn.14324","article-title":"Gabapentin for pain, movement disorders, and irritability in neonates and infants","volume":"62","author":"Burnsed","year":"2020","journal-title":"Dev Med Child Neurol"},{"issue":"9488","key":"10.1016\/j.ajem.2024.08.033_bb0020","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","article-title":"Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial","volume":"366","author":"Pandya","year":"2005","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.ajem.2024.08.033_bb0025","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1213\/ANE.0000000000001120","article-title":"The effect of preoperative gabapentin on postoperative nausea and vomiting: a meta-analysis","volume":"122","author":"Grant","year":"2016","journal-title":"Anesth Analg"},{"issue":"10","key":"10.1016\/j.ajem.2024.08.033_bb0030","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/anae.13179","article-title":"A systematic review and meta-regression analysis of prophylactic gabapentin for postoperative pain","volume":"70","author":"Doleman","year":"2015","journal-title":"Anaesthesia"},{"issue":"4","key":"10.1016\/j.ajem.2024.08.033_bb0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/10401230209147462","article-title":"New anticonvulsants: a review of applications for the management of substance abuse disorders","volume":"14","author":"Gentry","year":"2002","journal-title":"Ann Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.ajem.2024.08.033_bb0040","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: a randomized clinical trial","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.ajem.2024.08.033_bb0045","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamainternmed.2022.5268","article-title":"Trends in the concurrent prescription of opioids and gabapentin in the US, 2006 to 2018","volume":"183","author":"Peet","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.ajem.2024.08.033_bb0085","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s11126-016-9421-7","article-title":"Abuse of gabapentin is associated with opioid addiction","volume":"87","author":"Bastiaens","year":"2016","journal-title":"Psychiatry Q"},{"key":"10.1016\/j.ajem.2024.08.033_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.04.028","article-title":"Profiles of pregabalin and gabapentin abuse by postmortem toxicology","volume":"241","author":"H\u00e4kkinen","year":"2014","journal-title":"Forensic Sci Int"},{"issue":"7","key":"10.1016\/j.ajem.2024.08.033_bb0095","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.ajem.2024.08.033_bb0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40264-017-0595-1","article-title":"All-cause and drug-related medical events associated with overuse of gabapentin and\/or opioid medications: a retrospective cohort analysis of a commercially insured US population","volume":"41","author":"Peckham","year":"2018","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.ajem.2024.08.033_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case\u2013control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.ajem.2024.08.033_bb0110","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.ajem.2024.08.033_bb0115","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s11126-016-9421-7","article-title":"Abuse of gabapentin is associated with opioid addiction","volume":"87","author":"Bastiaens","year":"2016","journal-title":"Psychiatry Q"},{"key":"10.1016\/j.ajem.2024.08.033_bb0120","doi-asserted-by":"crossref","unstructured":"Kuehn B. M. (2022). Growing role of gabapentin in opioid-related overdoses highlights misuse potential and off-label prescribing practices. JAMA, 328(13), 1283\u20131285. doi:https:\/\/doi.org\/10.1001\/jama.2022.13659.","DOI":"10.1001\/jama.2022.13659"},{"issue":"3","key":"10.1016\/j.ajem.2024.08.033_bb0125","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/JGP.0b013e318190b8ef","article-title":"The epidemiology of substance use and disorders among middle aged and elderly community adults: national survey on drug use and health","volume":"17","author":"Blazer","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.ajem.2024.08.033_bb0130","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.drugalcdep.2017.08.027","article-title":"Age trends in rates of substance use disorders across ages 18-90: differences by gender and race\/ethnicity","volume":"180","author":"Vasilenko","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.ajem.2024.08.033_bb0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/RMHP.S168504","article-title":"Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance","volume":"11","author":"Peckham","year":"2018","journal-title":"Risk Manage Healthc Policy"},{"key":"10.1016\/j.ajem.2024.08.033_bb0140","series-title":"NFLIS-Drug Special Report: Gabapentin and Pregabalin Reported in NFLIS, 2011\u20132020, Springfield, VA","author":"U.S. Drug Enforcement Administration, Diversion Control Division","year":"2022"},{"issue":"2","key":"10.1016\/j.ajem.2024.08.033_bb0145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.burns.2021.12.006","article-title":"Prescribing of gabapentinoids with or without opioids after burn injury in the US, 2012-2018","volume":"48","author":"Polychronopoulou","year":"2022","journal-title":"Burns"},{"issue":"10","key":"10.1016\/j.ajem.2024.08.033_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.ajem.2024.08.033_bb0155","series-title":"Morbidity and Mortality Weekly Report. CDC Clinical Practice Guideline for Prescribing Opioids for Pain \u2014 United States","year":"2022"},{"issue":"1","key":"10.1016\/j.ajem.2024.08.033_bb0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","article-title":"Abuse potential of pregabalin: a systematic review","volume":"30","author":"Schjerning","year":"2016","journal-title":"CNS Drugs"},{"issue":"14","key":"10.1016\/j.ajem.2024.08.033_bb0165","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1007\/s11606-021-07314-2","article-title":"Association of state-imposed restrictions on gabapentin with changes in prescribing in medicare","volume":"37","author":"Grauer","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"9","key":"10.1016\/j.ajem.2024.08.033_bb0170","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32507","article-title":"State-to-state variation in opioid dispensing changes following the release of the 2016 CDC guideline for prescribing opioids for chronic pain","volume":"6","author":"Lyu","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.ajem.2024.08.033_bb0175","first-page":"246","article-title":"Trends in gabapentin prescribing in a commercially insured U.S. adult population, 2009-2016","volume":"26","author":"Pauly","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.ajem.2024.08.033_bb0180","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamainternmed.2022.5268","article-title":"Trends in the concurrent prescription of opioids and gabapentin in the US, 2006 to 2018","volume":"183","author":"Peet","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.ajem.2024.08.033_bb0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain \u2014 is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajem.2024.08.033_bb0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jep.12223","article-title":"Evidence, regulation and \u2018rational\u2019 prescribing: the case of gabapentin for neuropathic pain","volume":"21","author":"Ghinea","year":"2015","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.ajem.2024.08.033_bb0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/JEP.S124391","article-title":"Review about gabapentin misuse, interactions, contraindications and side effects","volume":"9","author":"Quintero","year":"2017","journal-title":"J Exp Pharmacol"},{"issue":"1","key":"10.1016\/j.ajem.2024.08.033_bb0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1528-1157.1996.tb00517.x","article-title":"Behavioral side effects of gabapentin in children","volume":"37","author":"Lee","year":"1996","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.ajem.2024.08.033_bb0070","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1528-1157.1995.tb01063.x","article-title":"Gabapentin toxicity in children manifesting as behavioral changes","volume":"36","author":"Wolf","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.ajem.2024.08.033_bb0075","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.14309\/00000434-201210001-00064","article-title":"Gabapentin for the treatment of chronic cough: a novel approach to treating a challenging clinical problem: 64","volume":"107","author":"Madanick","year":"2012","journal-title":"Official J Am Coll Gastroenterol"},{"issue":"2","key":"10.1016\/j.ajem.2024.08.033_bb0080","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/08860220802595476","article-title":"Gabapentin and uremic pruritus in hemodialysis patients","volume":"31","author":"Razeghi","year":"2009","journal-title":"Ren Fail"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675724004273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675724004273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T04:12:38Z","timestamp":1730347958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675724004273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":36,"alternative-id":["S0735675724004273"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2024.08.033","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gabapentinoid prescribing patterns and predictors utilizing neural networks: An analysis across emergency departments Nationwide between 2012 and 2021","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2024.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}